Farnesylated proteins and cell cycle progression

被引:59
作者
Tamanoi, F [1 ]
Kato-Stankiewicz, J [1 ]
Jiang, C [1 ]
Machado, I [1 ]
Thapar, N [1 ]
机构
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
关键词
farnesyltransferase inhibitor; cell cycle; Rheb; Ras; Rho; CNEP-E; F;
D O I
10.1002/jcb.10067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Post-translational modification of proteins by the addition of a farnesyl group is critical for the function of a number of proteins involved in signal transduction. Farnesylation facilitates their membrane association and also promotes protein-protein interaction. Recently, progress has been made in understanding the biological significance of farnesylation. First, effects of farnesyltransferase inhibitors (FTIs) on cancer cells have been examined using a variety of human cancer cells. This study showed that one of the major effects of FTIs is to alter cell cycle progression. Both G0/G1 enrichment and G2/M accumulation were observed depending on the cell line examined. Second, a number of novel farnesylated proteins have been characterized. Of these, Rheb and CENP-E,F are of particular interest. Rheb, a novel member of the Ras superfamily G-proteins, may play a role in the G1 phase of the cell cycle. CENP-E,F are centromere associated motors that play critical roles in mitosis. These results suggest important contributions of farnesylated proteins in the regulation of cell cycle progression. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:64 / 70
页数:7
相关论文
共 30 条
[1]   CENP-E as an essential component of the mitotic checkpoint in vitro [J].
Abrieu, A ;
Kahana, JA ;
Wood, KW ;
Cleveland, DW .
CELL, 2000, 102 (06) :817-826
[2]   Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules [J].
Ashar, HR ;
James, L ;
Gray, K ;
Carr, D ;
Black, S ;
Armstrong, L ;
Bishop, WR ;
Kirschmeier, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (39) :30451-30457
[3]   The farnesyl transferase inhibitor SCH 66336 induces a G2 → M or G1 pause in sensitive human tumor cell lines [J].
Ashar, HR ;
James, L ;
Gray, K ;
Carr, D ;
McGuirk, M ;
Maxwell, E ;
Black, S ;
Armstrong, L ;
Doll, RJ ;
Taveras, AG ;
Bishop, WR ;
Kirschmeier, P .
EXPERIMENTAL CELL RESEARCH, 2001, 262 (01) :17-27
[4]   A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis [J].
Barrington, RE ;
Subler, MA ;
Rands, E ;
Omer, CA ;
Miller, PJ ;
Hundley, JE ;
Koester, SK ;
Troyer, DA ;
Bearss, DJ ;
Conner, MW ;
Gibbs, JB ;
Hamilton, K ;
Koblan, KS ;
Mosser, SD ;
O'Neill, TJ ;
Schaber, MD ;
Senderak, ET ;
Windle, JJ ;
Oliff, A ;
Kohl, NE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :85-92
[5]  
Clark GJ, 1997, J BIOL CHEM, V272, P10608
[6]   The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells [J].
Crespo, NC ;
Ohkanda, J ;
Yen, TJ ;
Hamilton, AD ;
Sebti, SM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16161-16167
[7]   Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines [J].
Edamatsu, H ;
Gau, CL ;
Nemoto, T ;
Guo, L ;
Tamanoi, F .
ONCOGENE, 2000, 19 (27) :3059-3068
[8]   Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects [J].
Feldkamp, MM ;
Lau, N ;
Guha, A .
ONCOGENE, 1999, 18 (52) :7514-7526
[9]  
Feldkamp MM, 2001, CANCER RES, V61, P4425
[10]   The potential of farnesyltransferase inhibitors as cancer chemotherapeutics [J].
Gibbs, JB ;
Oliff, A .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :143-166